版本:
中国

BRIEF-XTL Biopharmaceuticals unveils expanded HCDR1 preclinical data for treatment of sjögren's syndrome

April 5 X T L Biopharmaceuticals Ltd

* X T L Biopharmaceuticals Ltd - XTL Biopharmaceuticals unveils expanded HCDR1 preclinical data for treatment of sjögren's syndrome

* X T L Biopharma - additional data shows statistically significant effect in gene expression of 2 additional genes that have role in pathogenesis of sjögren's syndrome Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐